Tag: Biopharmaceuticals

With a market valued at over $500 billion in 2023, biologics are revolutionizing modern medicine. Their distinctiveness lies in what makes biologics unique: their origin from living systems, large and complex molecular structure, and highly specific mechanism of action, differentiating them fundamentally from traditional chemical drugs.

In July 2003, the U.S. Food and Drug Administration (FDA) approved the once-daily HIV medication **Emtriva**. The biopharmaceutical company Gilead Sciences, Inc. holds the trademark and is responsible for the manufacturing and marketing of this essential antiretroviral drug.

Scorpion venom is one of the most expensive liquids in the world, with some estimates valuing it at $39 million per gallon [1.3.2, 1.9.4]. The answer to 'What is the drug called scorpion?' is complex; it refers not to a single substance but to a range of compounds, from an FDA-approved antivenom to revolutionary cancer-fighting agents [1.2.3, 1.4.1].

Priced at $4.25 million for a single infusion, Kyowa Kirin's Lenmeldy is currently the most expensive drug substance in the world. This one-time gene therapy is a groundbreaking treatment for the ultra-rare genetic disorder metachromatic leukodystrophy (MLD), highlighting the high costs associated with advanced therapeutic innovation.

Founded in 1876 by Colonel Eli Lilly, the company established its purpose as a pharmaceutical manufacturing business from its very inception. So, to definitively answer the question, **does Eli Lilly manufacture drugs?** Yes, it does, and has for nearly 150 years, developing an extensive, high-tech global manufacturing operation. This has allowed it to produce a massive portfolio of medicines, from insulin to modern therapies for obesity and oncology.

More than 160 monoclonal antibodies and related therapeutics were approved by the FDA as of mid-2024, a number that continues to grow rapidly. This reflects the increasing role of these highly specific biologic drugs in modern medicine, with the answer to the question, 'How many FDA approved monoclonal antibodies are there?' constantly evolving as new treatments reach the market.

In pharmaceutical research, the development of novel drug delivery systems has led to significant advancements in treating various diseases. One such innovation is the mucoadhesive gel, a semisolid formulation engineered to adhere to mucosal surfaces, thereby improving drug residence time and absorption. Its unique properties offer substantial advantages over traditional medications, especially for targeted or controlled-release applications.

In pharmacology and medicine, the acronym DSP doesn't refer to just one thing, creating confusion for patients and professionals alike. To clarify, this guide explores the primary uses for **what is a DSP used for?** in medication, from Downstream Processing in drug manufacturing to the role of a Direct Support Professional in patient care.

According to a 2021 report, the global peptide drug market was projected to increase significantly in value, underscoring the growing importance of what are the most impactful peptides in modern medicine. These powerful, yet precise, short chains of amino acids are revolutionizing treatment for a wide array of conditions, from metabolic disorders to autoimmune diseases.

Studies show that approximately 90% of all new drugs that enter clinical trials ultimately fail to gain FDA approval, highlighting the high-risk nature of pharmaceutical development [1.2.1, 1.2.3, 1.2.5]. This article explores what the FDA approval rate for drugs is and the factors that influence it.